April 21, 2017 / 1:50 PM / a year ago

BUZZ-Aurinia Pharmaceuticals: Up on additional kidney drug data

** Canadian drugmaker’s U.S.-listed shares up as much as 9.3 pct at $7.65 in early trading

** With more than 5.5 mln shares traded, it is the most actively traded stock on Nasdaq

** Company says its experimental drug, voclosporin, to treat lupus nephritis met all the goals in a mid-stage study at 48 weeks

** Voclosporin showed statistically significant improvement in speed and rates of partial and complete remission in its mid-stage study

** Lupus nephritis is a serious condition that involves kidney inflammation

** In partial remission, only some signs and symptoms of cancer wane, while in complete remission all signs of cancer disappear in response to treatment

** Up to Thursday’s close, stock had risen 233.3 pct YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below